2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease.

Autor:	Fargo KN; Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL., Aisen P; Department of Neurosciences, University of California San Diego School of Medicine, San Diego, CA., Albert M; Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD., Au R; Department of Neurology and Framingham Heart Study, Boston University School of Medicine, Boston, MD., Corrada MM; Department of Neurology and Department of Epidemiology, University of California, Irvine, CA., DeKosky S; Department of Neurology, University of Virginia, Charlottesville, VA; Department of Radiology and Department of Neurology, University of Pittsburgh, PA., Drachman D; Department of Neurology, University of Massachusetts Medical School, Worcester, MA., Fillit H; Alzheimer's Drug Discovery Foundation; Department of Geriatrics and Palliative Medicine and Department of Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY., Gitlin L; Department of Community-Public Health and Department of Psychiatry, Johns Hopkins University, Baltimore, MD., Haas M; Orion Bionetworks, Cambridge, MA., Herrup K; Division of Life Science and the State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Kowloon, Hong Kong., Kawas C; Department of Neurology, Department of Neurobiology & Behavior, and Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA., Khachaturian AS; National Biomedical Research Ethics Council, Rockville, MD., Khachaturian ZS; PAD2020, Rockville, MD., Klunk W; Department of Psychiatry, University of Pittsburgh, PA., Knopman D; Department of Neurology, Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN., Kukull WA; National Alzheimer's Coordinating Center (NACC); and Department of Epidemiology, University of Washington, Seattle, WA., Lamb B; Department of Neurosciences, Lerner Research Institute, The Cleveland Clinic, Cleveland, OH., Logsdon RG; Department of Psychosocial and Community Health, University of Washington, Seattle, WA., Maruff P; Florey Institute for Neuroscience and Mental Health, University of Melbourne; and CogState Ltd., Melbourne VIC, Australia., Mesulam M; Department of Neurology and Alzheimer's Disease Center, Feinberg School of Medicine, Northwestern University, Chicago, IL., Mobley W; Department of Neurosciences, University of California San Diego School of Medicine, San Diego, CA., Mohs R; Neuroscience Early Clinical Development, Eli Lilly and Company, Indianapolis, IN., Morgan D; Byrd Alzheimer's Institute, University of South Florida, Tampa, FL., Nixon RA; Department of Psychiatry and Department of Cell Biology, New York University Langone Medical Center, New York, NY; and The Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY., Paul S; Appel Alzheimer's Disease Research Institute, Weill Cornell Medical College, New York, NY; Foundation for the National Institutes of Health, Bethesda, MD., Petersen R; Department of Neurology, Mayo Clinic Alzheimer's Disease Research Center, Mayo Clinic College of Medicine, Rochester, MN., Plassman B; Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC., Potter W; Neuroscience Steering Committee of the Biomarkers Consortium, Foundation of the National Institutes of Health (emeritus)., Reiman E; Banner Alzheimer's Institute; and Department of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ., Reisberg B; Department of Psychiatry, New York University School of Medicine, New York, NY., Sano M; Department of Psychiatry; and Alzheimer's Disease Research Center, Mount Sinai School of Medicine, New York, NY., Schindler R; Pfizer, Inc., New York, NY., Schneider LS; Department of Psychiatry and the Behavioral Sciences and Department of Neurology, Keck School of Medicine; and Leonard Davis School of Gerontology; University of Southern California, Los Angeles, CA., Snyder PJ; Department of Neurology, Alpert Medical School of Brown University; and Department of Neurology, Rhode Island Hospital; Providence, RI., Sperling RA; Departments of Neurology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA., Yaffe K; Department of Psychiatry and Department of Neurology, University of California, San Francisco; and San Francisco VA Medical Center, CA., Bain LJ; Independent Science Writer, Elverson, PA., Thies WH; Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL., Carrillo MC; Division of Medical and Scientific Relations, Alzheimer's Association, Chicago, IL. Electronic address: mcarrillo@alz.org.
Jazyk:	angličtina
Zdroj:	Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2014 Oct; Vol. 10 (5 Suppl), pp. S430-52.
DOI:	10.1016/j.jalz.2014.08.103
Abstrakt:	With increasing numbers of people with Alzheimer's and other dementias across the globe, many countries have developed national plans to deal with the resulting challenges. In the United States, the National Alzheimer's Project Act, signed into law in 2011, required the creation of such a plan with annual updates thereafter. Pursuant to this, the US Department of Health and Human Services (HHS) released the National Plan to Address Alzheimer's Disease in 2012, including an ambitious research goal of preventing and effectively treating Alzheimer's disease by 2025. To guide investments, activities, and the measurement of progress toward achieving this 2025 goal, in its first annual plan update (2013) HHS also incorporated into the plan a set of short, medium and long-term milestones. HHS further committed to updating these milestones on an ongoing basis to account for progress and setbacks, and emerging opportunities and obstacles. To assist HHS as it updates these milestones, the Alzheimer's Association convened a National Plan Milestone Workgroup consisting of scientific experts representing all areas of Alzheimer's and dementia research. The workgroup evaluated each milestone and made recommendations to ensure that they collectively constitute an adequate work plan for reaching the goal of preventing and effectively treating Alzheimer's by 2025. This report presents these Workgroup recommendations. (Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu